{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T02:45:37Z","timestamp":1785725137104,"version":"3.56.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2023ZD0511500"],"award-info":[{"award-number":["2023ZD0511500"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015796","name":"Shanghai Lingjun Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015796","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M750532"],"award-info":[{"award-number":["2024M750532"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273234"],"award-info":[{"award-number":["82273234"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573384"],"award-info":[{"award-number":["82573384"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403964"],"award-info":[{"award-number":["82403964"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["SQ2025YFE0204194"],"award-info":[{"award-number":["SQ2025YFE0204194"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218707","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:04:35Z","timestamp":1783379075000},"page":"218707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["FGFR2 fusion-driven CXCL3 downregulation attenuates neutrophil recruitment in intrahepatic cholangiocarcinoma"],"prefix":"10.1016","volume":"657","author":[{"given":"Tao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Cheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Zi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Long","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Qiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Yang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao-Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Ying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Yong","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Wu","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3817-9117","authenticated-orcid":false,"given":"Guo-Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218707_bib1","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218707_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.canlet.2026.218707_bib3","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218707_bib4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J. Hepato-Biliary-Pancreatic Sci."},{"key":"10.1016\/j.canlet.2026.218707_bib5","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO-24-01383","article-title":"Swog S1815: a phase III randomized trial of gemcitabine, cisplatin, and Nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"43","author":"Shroff","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218707_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/hep.32624","article-title":"Proteogenomic characterization of cholangiocarcinoma","volume":"77","author":"Deng","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2026.218707_bib7","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2026.218707_bib8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218707_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218707_bib10","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1158\/2159-8290.CD-23-0728","article-title":"FGFR inhibition: understanding and overcoming resistance","volume":"13","author":"Tripathi","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218707_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.canlet.2026.218707_bib12","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1038\/ncomms7087","article-title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma","volume":"6","author":"Sia","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218707_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218707_bib14","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.1016\/j.annonc.2023.09.1401","article-title":"108P FGFR2 fusions and their impact on efficacy of standard chemotherapy in patients with biliary tract cancer","volume":"34","author":"Zheng-Lin","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218707_bib15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11523-022-00906-w","article-title":"Effect of FGFR2 alterations on overall and progression-free survival in patients receiving systemic therapy for intrahepatic cholangiocarcinoma","volume":"17","author":"Abou-Alfa","year":"2022","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.canlet.2026.218707_bib16","doi-asserted-by":"crossref","first-page":"e1734","DOI":"10.1093\/oncolo\/oyae170","article-title":"FGFR2 fusion\/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma","volume":"29","author":"Liu","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2026.218707_bib17","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00535-020-01735-2","article-title":"Molecular detection and clinicopathological characteristics of advanced\/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE study)","volume":"56","author":"Maruki","year":"2021","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.canlet.2026.218707_bib18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejca.2022.02.013","article-title":"Prognostic impact of FGFR2\/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study","volume":"166","author":"Rizzato","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218707_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218707_bib20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218707_bib21","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2026.218707_bib22","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1002\/cam4.5273","article-title":"Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: a phase II study","volume":"12","author":"Shi","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2026.218707_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216799","article-title":"Characterization of the distinct immune microenvironments between hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"588","author":"Jiang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218707_bib24","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jhep.2020.05.039","article-title":"Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma","volume":"73","author":"Zhang","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2026.218707_bib25","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2026.218707_bib26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-Origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218707_bib27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","article-title":"Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma","volume":"40","author":"Dong","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218707_bib28","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41467-024-44795-1","article-title":"Macro CD5L(+) deteriorates CD8(+)T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma","volume":"15","author":"Lu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218707_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41419-022-05406-3","article-title":"Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC\/PCAF\/AKT axis","volume":"14","author":"Guo","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218707_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40364-022-00361-9","article-title":"KSR2-14-3-3\u03b6 complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma","volume":"10","author":"Gao","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.canlet.2026.218707_bib31","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1158\/0008-5472.CAN-24-4576","article-title":"FGFR2 abrogation intercepts pancreatic ductal adenocarcinoma development","volume":"85","author":"Tonelli","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218707_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143759","article-title":"Neutrophil dynamics in the tumor microenvironment","volume":"131","author":"McFarlane","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218707_bib33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41698-022-00320-5","article-title":"Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies","volume":"6","author":"Lidsky","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2026.218707_bib34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/s41587-021-00869-9","article-title":"Single-cell CUT&Tag profiles histone modifications and transcription factors in complex tissues","volume":"39","author":"Bartosovic","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218707_bib35","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2026.218707_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1137510","article-title":"Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue","volume":"13","author":"Brandi","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218707_bib37","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ccell.2023.03.008","article-title":"Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-\u03b2 activation","volume":"41","author":"Mousset","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218707_bib38","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","article-title":"Neutrophil plasticity in the tumor microenvironment","volume":"133","author":"Giese","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218707_bib39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.tcb.2018.12.006","article-title":"Targeting cancer through the epigenetic features of telomeric regions","volume":"29","author":"Vaquero-Sedas","year":"2019","journal-title":"Trends Cell Biol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T02:19:22Z","timestamp":1785723562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526004714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"alternative-id":["S0304383526004714"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218707","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGFR2 fusion-driven CXCL3 downregulation attenuates neutrophil recruitment in intrahepatic cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218707"}}